Drug-eluting stent thrombosisCardiovascular Research, Physiology Institute, University of Zürich and Cardiology, Cardiovascular Center, University Hospital Zürich, and Zürich Center for Integrative Human Physiology (ZIHP), University of Zurich
Cardiovascular Research, Physiology Institute, University of Zürich and Cardiology, Cardiovascular Center, University Hospital Zürich, and Zürich Center for Integrative Human Physiology (ZIHP), University of Zurich
Cardiovascular Research, Physiology Institute, University of Zürich and Cardiology, Cardiovascular Center, University Hospital Zürich, and Zürich Center for Integrative Human Physiology (ZIHP), University of Zurich felix.tanner{at}access.uzh.ch Stent thrombosis is a rare complication following stent implantation; if it occurs, however, it is associated with a high morbidity and mortality. Despite reduced rates of restenosis, drug-eluting stents (DES) have not reduced the incidence of stent thrombosis as compared with bare-metal stents (BMS). Patient-, lesion-, and procedure-related factors as well as thrombogenicity of the stent itself are involved in the pathogenesis of stent thrombosis. Furthermore, early cessation of dual antiplatelet therapy correlates with an increased risk of stent thrombosis. This review focuses on clinical evidence and pathophysiological mechanisms of stent thrombosis with DES, particularly highlighting prothrombotic effects of the stent itself.
Key Words: acute coronary syndrome • drug-eluting stent • stent thrombosis • re-endothelialization • tissue factor
This version was published on February
1, 2009 Therapeutic Advances in Cardiovascular Disease, Vol. 3, No. 1,
45-52 (2009) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
